Edward Belk Perry Jr, MD, MHS
Associate Professor of Medicine (Medical Oncology & Hematology)DownloadHi-Res Photo
Cards
Education
MHS
Yale University
Yale University
MD
University of Alabama
University of Alabama
BA
University of Mississippi
University of Mississippi
Publications Overview
- 43 Publications
- 3,574 Citations
- 22 Yale Co-Authors
About
Copy Link
Titles
Associate Professor of Medicine (Medical Oncology & Hematology)
Biography
Dr. Perry is an Associate Professor in the Department of Internal Medicine (Medical Oncology & Hematology) at Yale School of Medicine.
Last Updated on February 19, 2026.
Departments & Organizations
- All Institutions
- Hamburg House Affiliates
Education & Training
- MHS
- Yale University
- Hematology/oncology fellowship
- University of Connecticut
- Internal medicine residency
- George Washington University
- Psychiatry residency
- Vanderbilt University
- MD
- University of Alabama
- BA
- University of Mississippi
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
Internal Medicine
- Certification Organization
- AB of Internal Medicine
Psychiatry
- Certification Organization
- AB of Psychiatry & Neurology
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
Research
Copy Link
Publications
2019
Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System
Liu Y, Fitzgerald B, Perry E, Pathak A, Chao HH. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System. Journal Of Investigative Medicine High Impact Case Reports 2019, 7: 2324709619850216. PMID: 31132886, PMCID: PMC6540500, DOI: 10.1177/2324709619850216.Peer-Reviewed Case Reports and Technical NotesCitationsAltmetricMeSH Keywords and ConceptsConceptsSquamous cell carcinomaSpindle cell squamous cell carcinomaCutaneous squamous cell carcinomaCell carcinomaCentral nervous systemNeurological deficitsAdvanced diseaseAnti-PD-1 monoclonal antibody treatmentNervous systemAnti-PD-1 therapyCentral nervous system metastasesProgressive left-sided weaknessSquamous cell carcinoma metastaticLeft-sided weaknessNervous system metastasesProgressive neurological deficitsProgression-free survivalDurable clinical responsesMonoclonal antibody treatmentRare spindle-cell variantSpindle cell variantDurability of effectDrug Administration approvalRadiation therapy optionsCarcinoma metastatic
2014
Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans
Mathalon DH, Ahn KH, Perry EB, Cho HS, Roach BJ, Blais RK, Bhakta S, Ranganathan M, Ford JM, D’Souza D. Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans. Frontiers In Psychiatry 2014, 5: 3. PMID: 24478731, PMCID: PMC3900858, DOI: 10.3389/fpsyt.2014.00003.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAuditory event-related brain potentialsEvent-related brain potentialsTest sessionsBehavioral effectsAmplitude of P3aDissociative Symptoms ScaleNicotinic acetylcholine receptor stimulationBrain potentialsP3b amplitudeMMN amplitudeP3a amplitudeNovel stimuliNeurophysiological measuresNMDA receptor hypofunctionN-methyl-D-aspartate (NMDA) receptor hypofunctionNegative Syndrome ScaleEffects of nicotineReceptor hypofunctionNeurocognitive impairmentCounterbalanced mannerP3aSchizophrenia-like effectsSyndrome ScaleInjections of nicotineInteraction of ketamine
2013
Primary cutaneous anaplastic large-cell lymphoma.
Perry E, Karajgikar J, Tabbara IA. Primary cutaneous anaplastic large-cell lymphoma. American Journal Of Clinical Oncology 2013, 36: 526-9. PMID: 21552098, DOI: 10.1097/COC.0b013e3182185aa2.Peer-Reviewed Original Research
2012
Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study
D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. Neuropsychopharmacology 2012, 38: 492-503. PMID: 23093223, PMCID: PMC3547200, DOI: 10.1038/npp.2012.208.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCognitive retrainingCognitive deficitsVerbal Working MemoryCognitive remediation strategiesAttention/vigilanceBasic information processingIndividual test performanceGlobal cognitive indexWorking memoryD-serineCognitive indicesCombination of pharmacotherapyTest performanceInformation processingMulticenter international clinical trialParallel group designSchizophrenia subjectsCollaborative pilot studyInternational clinical trialsUS samplePreliminary findingsCombination pharmacotherapySchizophreniaClinical trialsOutcome measuresNaltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans
Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D'Souza DC. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal Of Neuropsychopharmacology 2012, 15: 1251-1264. PMID: 22243563, DOI: 10.1017/s1461145711001830.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAdolescentAdultAttentionBehaviorCognitionCognition DisordersDouble-Blind MethodDronabinolDrug InteractionsEuphoriaFemaleHallucinogensHumansInhibition, PsychologicalInjections, IntravenousMaleMarijuana AbuseMemoryMental RecallMiddle AgedNaltrexoneNarcotic AntagonistsOrientationPerceptionPsychoses, Substance-InducedRecognition, PsychologyRewardYoung AdultConceptsCognitive effectsHealthy human subjectsPerceptual alterationsHuman subjectsTHC effectsCognitive impairmentΔ9-tetrahydrocannabinolActive naltrexoneDouble-blind mannerTest dayPsychotomimetic effectsPreclinical evidenceMOR antagonistΜ-opioidCB1R agonistPsychiatric illnessPrecise natureHealthy humansDrug AdministrationReceptor systemNaltrexoneEffect of pretreatmentAnxietyPlaceboTHC
2011
Preliminary Findings on the Interactive Effects of IV Ethanol and IV Nicotine on Human Behavior and Cognition: A Laboratory Study
Ralevski E, Perry EB, D’Souza D, Bufis V, Elander J, Limoncelli D, Vendetti M, Dean E, Cooper TB, McKee S, Petrakis I. Preliminary Findings on the Interactive Effects of IV Ethanol and IV Nicotine on Human Behavior and Cognition: A Laboratory Study. Nicotine & Tobacco Research 2011, 14: 596-606. PMID: 22180582, PMCID: PMC6281082, DOI: 10.1093/ntr/ntr258.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRey Auditory Verbal Learning TaskAuditory Verbal Learning TaskVerbal learning taskAcute intravenous alcoholSubjective alcohol effectsBiphasic Alcohol Effects ScaleAlcohol-induced deficitsAlcohol-induced impairmentDoses of alcoholActive nicotineInteractive effectsTest dayCognitive inhibitionVerbal learningCognitive performanceLearning taskSubjective intoxicationAlcohol effectsHuman behaviorNicotine effectsIntravenous alcoholAlcohol infusionManner oneSubjective effectsCognitionThe safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories
Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D’Souza D, The Yale THC Study Group. The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 2011, 219: 885-896. PMID: 21845389, DOI: 10.1007/s00213-011-2417-y.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdverse eventsPost-study periodCareful subject selectionMinor adverse eventsPhysical adverse eventsFrequent side effectsLong-term followCannabinoid receptor systemFaster infusion rateCannabinoid receptor ligandsIntravenous THCPlacebo infusionCannabinoid systemInfusion rateStudy participationSide effectsAbuse liabilityHigh dosesReceptor systemΔ9-tetrahydrocannabinolInfusionPsychoactive effectsReceptor ligandsTest daySubjects
2010
Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler
Esterlis I, Mitsis EM, Batis JC, Bois F, Picciotto MR, Stiklus SM, Kloczynski T, Perry E, Seibyl JP, McKee S, Staley JK, Cosgrove KP. Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. The International Journal Of Neuropsychopharmacology 2010, 14: 389-398. PMID: 21029513, PMCID: PMC3510008, DOI: 10.1017/s1461145710001227.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNicotine inhalerWithdrawal symptomsReceptor occupancyTobacco smokingLow nicotine cigarettesAdministration of nicotineHigh receptor occupancyDoses of nicotineNicotinic acetylcholine receptorsInhaler useTobacco smokersBaseline scanRegular cigarettesInhalerConstant infusionAcetylcholine receptorsSPECT studiesCigarettesSymptomsBeta 2Significant decreaseNicotineSignificant differencesSmokingNAChRsClinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation Scale
Sewell RA, Perry EB, Karper LP, Bell MD, Lysaker P, Goulet JL, Brenner L, Erdos J, d'Souza DC, Seibyl JP, Krystal JH. Clinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation Scale. Schizophrenia Research 2010, 124: 1-12. PMID: 20855185, DOI: 10.1016/j.schres.2010.08.036.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsNeurological Evaluation ScaleAbnormal Involuntary Movement ScaleDigit Symbol Substitution TaskWisconsin Card Sorting TestNeurologic deficitsClinical significanceExtrapyramidal Symptom Rating ScaleMore extrapyramidal symptomsBarnes Akathisia ScaleDetailed clinical assessmentNeurological soft signsSymptom Rating ScaleNegative Syndrome ScaleHigher AIMS scoresEvaluation ScaleNeurological deficitsExtrapyramidal symptomsClinical correlatesDeficit syndrome schizophreniaClinical evaluationClinical assessmentAIMS scoresLower PANSSMovement ScaleSoft signsSPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals
Esterlis I, Cosgrove KP, Petrakis IL, McKee SA, Bois F, Krantzler E, Stiklus SM, Perry EB, Tamagnan GD, Seibyl JP, Krystal JH, Staley JK. SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals. Drug And Alcohol Dependence 2010, 108: 146-150. PMID: 20074869, PMCID: PMC2871672, DOI: 10.1016/j.drugalcdep.2009.12.006.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsDrinks/occasionNicotinic acetylcholine receptorsControl nonsmokersAcetylcholine receptorsHeavy drinkersHeavy drinkingLast alcoholic beverageHeavy alcohol drinkersHeavy alcoholSingle photon emissionSeverity of drinkingEffect of ageTobacco smokingAlcohol drinkersAlcohol drinkingCommon neural substrateNonsmokersAlcohol consumptionReceptor availabilityLarger studyAlcohol drinksAlcohol use behaviorsAddictive disordersDrinkersNeural substrates
Academic Achievements & Community Involvement
Copy Link
Activities
activity PDQ Supportive and Palliative Care Editorial Board
2016 - PresentAdvisory BoardsBoard MemberDetailsNational Cancer InstituteProduce and maintain evidence-based cancer information summaries for the NCI's comprehensive public databaseactivity Yale Institutional Review Board
09/01/2022 - PresentCommitteesMemberactivity Schwartz Rounds at VA Connecticut Healthcare System
09/18/2022 - 09/18/2022Oral PresentationAssociation of VA Hematology/Oncology Annual MeetingDetailsSan Diego, CA, United StatesSponsored by Association of VA Hematology/Oncologyactivity Fatigue in Breast Cancer Patients Undergoing Irradiation
09/17/2021 - 09/17/2021LectureDepartment of Psychiatry Grand RoundsDetailsUniversity of Connecticut School of MedicineSponsored by University of Connecticut School of Medicine
News
Copy Link